Ratiometric Fluorescent Chemosensing for Predicting Response to Irinotecan-Based Therapies in Pancreatic Ductal Adenocarcinoma
for predicting FOLFIRINOX prognosis across patient samples ranging in biological complexity and advocate for the translation of such technologies in the clinic to guide clinician choice of chemotherapeutic treatment.
Authors
- Karishma Kailass (ORCID: https://orcid.org/0009-0003-7052-490X)
- Bhaswati Sarcar
- Jason B. Fleming (ORCID: https://orcid.org/0000-0002-8796-5627)
- Alexandra F. Tassielli (ORCID: https://orcid.org/0009-0009-1445-8227)
- Ruifan Dai
- Andrew A. Beharry (ORCID: https://orcid.org/0000-0003-1505-2375)
- Francisca Beato (ORCID: https://orcid.org/0009-0003-0147-4013)
- Margaret Park
- Jennifer Permuth
Institutions
- University of Toronto (CA)
- Moffitt Cancer Center (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- ACS Sensors
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1021/acssensors.5c04552
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Florida Department of Health
- Cancer Research Society
- Natural Sciences and Engineering Research Council of Canada
- National Cancer Institute